ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)#881226
- Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome#843436
- Living With Guillain-Barré Syndrome as Children.#1102803
- Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment#826450
- Methylprednisolone as an adjunct to intravenous immunoglobulin in pediatric Guillain-Barré syndrome: a prospective comparative study#5550
Record · ID 867246
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive